Organon & Co. Sees Unusually High Options Volume (NYSE:OGN)

Organon & Co. (NYSE:OGN) was the recipient of unusually large options trading on Friday. Investors bought 20,849 call options on the company. This represents an increase of approximately 537% compared to the average volume of 3,274 call options.

Wall Street Analyst Weigh In

OGN has been the topic of a number of analyst reports. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Barclays lifted their price objective on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $8.50.

Organon & Co. Trading Up 28.7%

OGN opened at $8.89 on Friday. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.24. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of 12.52, a PEG ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. The business has a fifty day moving average price of $6.93 and a 200 day moving average price of $7.76.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same period in the previous year, the firm earned $0.90 earnings per share. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. Sell-side analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Monday, February 23rd. Organon & Co.’s payout ratio is presently 11.27%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Foster Dykema Cabot & Partners LLC acquired a new position in shares of Organon & Co. during the 3rd quarter worth about $29,000. Rothschild Investment LLC lifted its holdings in shares of Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after purchasing an additional 1,646 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Organon & Co. by 70.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company’s stock valued at $53,000 after purchasing an additional 2,109 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of Organon & Co. in the 4th quarter valued at about $44,000. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.